Hsiaohsuan Kuo, PhD

Moderna, Inc.

Disclosure(s): Moderna, Inc.: Employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-1446) Durable RSV-Specific CD4⁺ T-Cell Responses Following mRNA-1345 Vaccination in Adults at Increased Risk of Lower Respiratory Tract Disease Due to RSV
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1447) T-Cell Responses Following Two Doses of mRNA-1345 in Adult Solid Organ Transplant Recipients
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1454) mRNA-Based Respiratory Syncytial Virus Vaccine mRNA-1345 Induces Robust, Polyfunctional, and Durable CD4+ and CD8+ T Cell Responses with Similar Features in Adults Across Age Groups
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET